Page 1

Xenetic BIOSCIENCES Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform Expanded collaborative research initiatives reinforce the Company's long - term DNase development strategy Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I - mediated NET targeting Exhibit 99.1 - Continued royalty generation provides recurring , non - dilutive funding to support continued investment in core development programs FRAMINGHAM , MA ( August 7 , 2026 ) Xenetic Biosciences , Inc. ( NASDAQ : XBIO ) ( “ Xenetic ” or the “ Company ” ) , a biopharmaceutical company focused on advancing innovative immuno - oncology technologies addressing difficult to treat cancers , today reported financial results for the quarter ended June 30 , 2026 , and provided a corporate update on continued execution of its long - term strategy to advance its proprietary DNase platform through scientific collaboration and translational research . Recent Highlights Positive preclinical and translational data presented at the 2026 American Society of Clinical Oncology ( ASCO ) Annual Meeting demonstrating that DNase I significantly enhanced CAR T - cell expansion , persistence , tumor control and survival across preclinical hematologic cancer models Announced that collaboration partner , PeriNess Ltd. , received approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an investigator - initiated exploratory study evaluating systemic recombinant human DNase I in combination with anti - CD19 CAR T - cell therapy in patients with large B - cell lymphoma at Tel Aviv Sourasky Medical Center Received approximately $ 1.5 million in royalty revenue during the first six months of 2026 " We continue to generate strong translational data as evidenced by what was presented at ASCO , further supporting the potential of DNase I as a differentiated adjunct therapy designed to improve the efficacy and durability of CAR T - cell therapies , " said James Parslow , Interim Chief Executive Officer and Chief Financial Officer of Xenetic . " Throughout the second quarter , we continued expanding the scientific foundation supporting our proprietary DNase technology while prudently allocating capital toward activities designed to both inform future clinical development and advance our ongoing strategic review process . We believe this disciplined approach , combined with continued royalty revenue from our legacy PolyXen technology , positions Xenetic to pursue long - term opportunities that have the potential to create meaningful value for both patients and shareholders . " Xenetic is advancing its proprietary DNase platform as a differentiated approach designed to enhance the effectiveness of existing cancer therapies by targeting neutrophil extracellular traps ( NETs ) , an increasingly recognized driver of tumor progression , immune suppression and therapeutic resistance . Through collaborations with leading academic institutions , the Company continues to expand the scientific understanding of NET biology while generating translational evidence intended to inform future clinical development and strengthen the long - term potential of its platform .